Novo rare disease lead hails acquired candidate as "significant addition" to portfolio
After the announcement of Novo Nordisk’s acquisition of Forma Therapeutics, all eyes are on the latter’s primary drug candidate, etavopivat, which is currently being tested in phase II/III.
by marketwire, translated by catherine brett
Novo Nordisk is strengthening its efforts within rare blood disorders through the USD 1.1bn acquisition of Forma Therapeutics, especially within sickle cell disease.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk to acquire Forma Therapeutics in USD 1.1bn deal
For subscribers
Novo Nordisk enters USD 6.3m legal settlement in US
For subscribers
Novo Nordisk to start human trial of new diabetes drug
For subscribers
.jpg&w=384&q=75)
